NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Diagnostics Advisory Committee (DAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 26 October 2023 at 10:00

**Location:** Via Zoom

# Committee members present

1. Brian Shine (Chair) Present for all items
2. Neil Hawkins (Vice Chair) Present for all items
3. Anne Scott Present for all items
4. Alex Novak Present for all items
5. Diane Davies Present for all items
6. Ghada Ahmed Present for all items
7. Keith Abrams Present for all items
8. Matt Stevenson Present for all items
9. Patrick McGinley Present for all items
10. Radha Ramachandran Present for all items
11. Rashmi Kumar Present for all items
12. Rebecca Allcock Present for items 1 to 4.1.3
13. Farai Goromonzi Present for all items
14. Michael Morton Present for all items
15. Sam Creavin Present for all items
16. John Cairns Present for all items

# NICE staff present:

Mark Chapman, Interim Director of Health Technologies Present for items 1 to 4.1.3

Rebecca Albrow, Associate Director, Diagnostics Assessment Present for all items

Programme (DAP)

Frances Nixon, Health Technology Assessment Adviser, DAP Present for all items

Jacob Grant, Health Technology Assessment Analyst, DAP Present for all items

Sana Issa, Meetings in Public Coordinator Present for items 1 to 4.1.6

Lyn Davies, Meetings in Public Coordinator Present for items 1 to 4.1.6

Donna Barnes, Project Manager, DAP Present for all items

Catherine Pank, Project Manager, Medical Present for items 1 to 4.2.3 Technologies Evaluation Programme

Ruth Melville, Senior Medical Editor Present for all items

Suzie Panek, Finance Analyst Present for all items

Matthew Brown, Digital Media Manager Present for all items

# External assessment group representatives present:

Paul Tappenden, Professor of Health Economic Present for items 1 to 4.1.6

Modelling School of Health and Related

Research

Katy Cooper, Senior Research Fellow, Present for items 1 to 4.1.6

School of Health and Related Research

# Specialist committee members present:

Britta Stordal, Senior Lecturer in Medical Sciences, Present for items 1 to 4.1.3

Middlesex University London

Suzanne Frank, Advanced Specialist Breast Present for all items

Cancer Pharmacist, The Christie Hospital

NHS Trust

Caroline Graham, Lay specialist Present for all items

Mark Davies, Consultant in Medical Oncology, Present for all items

Swansea Bay University Health Board

Muireann Kelleher, Consultant Medical Present for all items

Oncologist, St George’s University Hospital

NHS Foundation Trust

# Observers present:

Jessica Wilcock, Technical Analyst, DAP Present for all items

Ziqi Zhou, Technical Analyst, DAP Present for all items

Michael Kertanga, Associate Technical Analyst, Present for items 1 to 4.1.3

Interventional Procedures

Enna Christmas, Associate Technical Analyst, Present for all items

DAP

1. Introduction to the meeting
	1. The chair welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Jonathan Weir-McCall, Joy Allen, Michael Messenger and Stuart McIntosh.
2. News and announcements
	1. None.
3. Minutes from the last meeting
	1. The committee approved the minutes of the committee meeting held on 28 September 2023.
4. Evaluation of Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node positive early breast cancer

Part 1 – Open session

* + 1. The chair welcomed specialist committee member, external assessment group representatives, members of the public and company representatives from Agendia N.V., Exact Sciences, Myriad, Putnam PHMR, and Veracyte.

The chair asked all committee members and specialist committee members to indicate if they had any further interests to declare, in addition to those declared in advance of the meeting. All interests declared for this assessment are listed on the registers available on the NICE website here: <https://www.nice.org.uk/guidance/indevelopment/gid-dg10075>

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node positive early breast cancer.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

The Chair thanked the external assessment group, company representatives, and public observers for their attendance at the meeting.

* + 1. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and the external assessment group, manufacturer representatives and public observers left the meeting.

Part 2 – Closed session

The committee discussed confidential information submitted for this item.

The committee discussed next steps.

The committee then agreed on the content of the draft guidance. The committee decision was reached by consensus.

The committee asked the NICE technical team to prepare the draft guidance in line with their decisions.

1. Date of the next meeting

The next meeting of the Diagnostics Advisory Committee (DAC) will be held on Wednesday 29 November 2023 and will start promptly at 09:00